



Imagin Medical Announces \$80,000 Financing from Bigger Capital, LP

Innovative Cancer Treatment Company Receives Additional Funding

Vancouver, British Columbia - November 20, 2023 – Imagin Medical Inc. (“Imagin”) which is developing the innovative enCAGE™ Coil Precision Ablation System and the i/Blue™ Imaging System for the treatment of prostate cancer and bladder cancer respectively today announced the completion of a \$80,000 Note transaction with Bigger Capital Fund, LP. In consideration of the loan, Imagin has issued the lender 666,666 share purchase warrants, each exercisable at US\$0.40 per share for a period of five years. The proceeds will be utilized for general corporate purposes.

About Imagin Medical

Imagin Medical is building a best-in-class Urologic Oncology company developing proprietary technologies to better visualize and treat urologic cancers, including bladder and prostate cancer through minimally invasive surgery. The Company believes the i/Blue Imaging System, with its advanced proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting bladder cancer. The enCAGE Coil Prostate Cancer Precision Ablation System, a focal therapy bipolar radio frequency-based probe enabling precise pre-set margins that addresses the limitations of other forms of prostate cancer treatment that lack the ability to precisely target only the cancer cells improve outcomes and quality of life. Learn more at www.imaginmedical.com.

Media and Investor Contacts

Jim Hutchens, President & CEO, jhutchens@imaginmedical.com

John Vacha, Vice President & CFO, jvacha@imaginmedical.com